Nabriva Therapeutics AG Company Profile (NASDAQ:NBRV)

About Nabriva Therapeutics AG

Nabriva Therapeutics AG logoNabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). The Company also develops BC-7013, a semi-synthetic compound derived from pleuromutilin for the topical treatment of Gram-positive infections, including uncomplicated skin and skin structure infections (uSSIs). It is a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NBRV
  • CUSIP:
Key Metrics:
  • Previous Close: $10.78
  • 50 Day Moving Average: $8.90
  • 200 Day Moving Average: $6.82
  • 52-Week Range: $3.52 - $11.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.19
  • P/E Growth: 0.00
  • Market Cap: $228.12M
  • Outstanding Shares: 21,280,000
  • Beta: 1.23
Debt:
  • Current Ratio: 5.87%
  • Quick Ratio: 5.87%
Additional Links:
Companies Related to Nabriva Therapeutics AG:

Analyst Ratings

Consensus Ratings for Nabriva Therapeutics AG (NASDAQ:NBRV) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.80 (46.57% upside)

Analysts' Ratings History for Nabriva Therapeutics AG (NASDAQ:NBRV)
Show:
DateFirmActionRatingPrice TargetDetails
2/16/2017Cantor FitzgeraldInitiated CoverageBuy$14.00View Rating Details
2/6/2017HC WainwrightReiterated RatingBuy$16.00View Rating Details
1/31/2017WedbushReiterated RatingPositive -> Outperform$13.00View Rating Details
12/20/2016RBC Capital MarketsSet Price TargetBuy$22.00View Rating Details
10/27/2016Leerink SwannReiterated RatingOutperform$14.00View Rating Details
1/27/2016GabelliInitiated CoverageBuy$14.00View Rating Details
11/12/2015Needham & Company LLCReiterated RatingBuy$15.00View Rating Details
11/12/2015Royal Bank of CanadaBoost Price TargetOutperform$21.00 -> $22.00View Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for Nabriva Therapeutics AG (NASDAQ:NBRV)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Nabriva Therapeutics AG (NASDAQ:NBRV)
Current Year EPS Consensus Estimate: $-2.5400 EPS
Next Year EPS Consensus Estimate: $-2.5700 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.58)($0.58)($0.58)
Q3 20162($0.65)($0.50)($0.58)
Q4 20162($0.70)($0.16)($0.43)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nabriva Therapeutics AG (NASDAQ:NBRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nabriva Therapeutics AG (NASDAQ:NBRV)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Nabriva Therapeutics AG (NASDAQ:NBRV)
DateHeadline
us.rd.yahoo.com logoA growing threat could kill 10 million people a year by 2050 (NASDAQ:NBRV)
us.rd.yahoo.com - February 24 at 4:09 PM
finance.yahoo.com logoThere's a growing threat that could kill 10 million people a year by 2050 (NASDAQ:NBRV)
finance.yahoo.com - February 23 at 6:49 PM
News IconNabriva Therapeutics AG NBRV Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:NBRV)
www.bioportfolio.com - February 21 at 6:08 PM
finance.yahoo.com logoAlly Bridge Group Expands European Life Science Portfolio with New Investments and Establishes Presence in Europe (NASDAQ:NBRV)
finance.yahoo.com - February 21 at 6:08 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:NBRV)
biz.yahoo.com - February 16 at 6:20 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:NBRV)
biz.yahoo.com - February 13 at 7:56 PM
finance.yahoo.com logoNabriva Therapeutics to Participate in Two Investor Conferences in February (NASDAQ:NBRV)
finance.yahoo.com - February 8 at 7:40 PM
streetinsider.com logoNabriva (NBRV) Says No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin (NASDAQ:NBRV)
www.streetinsider.com - February 2 at 7:39 PM
tmcnet.com logoNabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia (NASDAQ:NBRV)
www.tmcnet.com - February 2 at 7:39 PM
biz.yahoo.com logoNABRIVA THERAPEUTICS AG Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fina (NASDAQ:NBRV)
biz.yahoo.com - January 9 at 7:28 PM
News IconNabriva Therapeutics AG NBRV Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:NBRV)
www.bioportfolio.com - January 5 at 8:31 PM
publicnow.com logoNabriva Announces Closing of Rights Offering and Underwritten Offering (NASDAQ:NBRV)
us.rd.yahoo.com - December 20 at 12:43 PM
publicnow.com logoNabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia (NASDAQ:NBRV)
www.publicnow.com - December 20 at 12:43 PM
4-traders.com logoNabriva Therapeutics : Announces Results of Rights Offering and Pricing of Underwritten Offering (NASDAQ:NBRV)
www.4-traders.com - December 16 at 12:40 AM
finance.yahoo.com logoNabriva Announces Results of Rights Offering and Pricing of Underwritten Offering (NASDAQ:NBRV)
finance.yahoo.com - December 14 at 7:26 PM
capitalcube.com logoNabriva Therapeutics AG :NBRV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 (NASDAQ:NBRV)
www.capitalcube.com - December 5 at 6:47 PM
us.rd.yahoo.com logo4:02 pm Nabriva Therapeutics announces terms of its rights offering for up to 588,127 common shares to its existing common shareholders and ADS holders (NASDAQ:NBRV)
us.rd.yahoo.com - November 30 at 11:56 PM
globenewswire.com logoNabriva Announces Terms of Rights Offering (NASDAQ:NBRV)
globenewswire.com - November 30 at 11:32 AM
4-traders.com logoNabriva Therapeutics : Announces Terms of Rights Offering (NASDAQ:NBRV)
www.4-traders.com - November 30 at 11:32 AM
publicnow.com logoNabriva Announces Change in Record Date for Planned Rights Offering (NASDAQ:NBRV)
www.publicnow.com - November 22 at 10:38 AM
4-traders.com logoNabriva Therapeutics : reports 3Q loss (NASDAQ:NBRV)
www.4-traders.com - November 17 at 10:12 AM
sg.finance.yahoo.com logoNabriva Therapeutics reports 3Q loss (NASDAQ:NBRV)
sg.finance.yahoo.com - November 16 at 10:02 AM
publicnow.com logoNabriva Reports Third Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - November 16 at 10:02 AM
publicnow.com logoNabriva Announces Planned Rights Offering and Sets Record Date (NASDAQ:NBRV)
www.publicnow.com - November 11 at 6:05 PM
4-traders.com logoNabriva Therapeutics : Announces Presentations at Upcoming IDWeek 2016 (NASDAQ:NBRV)
www.4-traders.com - October 22 at 10:27 AM
publicnow.com logoNabriva Announces Presentations at Upcoming IDWeek 2016 (NASDAQ:NBRV)
www.publicnow.com - October 20 at 12:06 PM
finance.yahoo.com logoNabriva to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:NBRV)
finance.yahoo.com - September 6 at 11:03 AM
finance.yahoo.com logoShould Nabriva Therapeutics (NBRV) Be On Your Radar Now? (NASDAQ:NBRV)
finance.yahoo.com - September 6 at 11:03 AM
finance.yahoo.com logoNabriva to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:NBRV)
finance.yahoo.com - August 10 at 9:29 AM
publicnow.com logoNabriva Reports Second Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - August 9 at 9:35 AM
publicnow.com logoNabriva Announces Nomination of Candidates for Its Supervisory Board (NASDAQ:NBRV)
www.publicnow.com - July 25 at 7:28 AM
fxpips.com logoMost Advanced Stocks on NASDAQ (NASDAQ:NBRV)
www.fxpips.com - July 20 at 9:18 AM
finance.yahoo.com logoF2G Ltd Announces the Appointment of Ralf Schmid to the Position of Chief Financial Officer (NASDAQ:NBRV)
finance.yahoo.com - July 11 at 4:00 AM
publicnow.com logoNabriva to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - July 5 at 7:21 AM
nasdaq.com logoEuropean ADRs Marginally Higher as Healthcare Stocks See Mixed Fortunes (NASDAQ:NBRV)
www.nasdaq.com - July 1 at 6:23 PM
nasdaq.com logoNabriva Presents Data on Lefamulin at the American Society of Microbiology (ASM) Microbe 2016 Conference (NASDAQ:NBRV)
www.nasdaq.com - June 20 at 6:16 PM
publicnow.com logoNabriva to Present at the JMP Securities Life Sciences Conference (NASDAQ:NBRV)
www.publicnow.com - June 14 at 7:19 AM
capitalcube.com logoNabriva Therapeutics AG :NBRV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 (NASDAQ:NBRV)
www.capitalcube.com - June 6 at 2:31 PM
marketwatch.com logoNabriva Therapeutics AG (US: NBRV) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:NBRV)
www.marketwatch.com - June 1 at 6:52 PM
publicnow.com logoNabriva Therapeutics AG (Nasdaq: NBRV) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:NBRV)
www.publicnow.com - May 31 at 10:22 AM
publicnow.com logoNabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference (NASDAQ:NBRV)
www.publicnow.com - May 16 at 7:32 AM
publicnow.com logoNabriva to Present at the UBS Global Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - May 11 at 7:22 AM
publicnow.com logoNabriva Reports First Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - May 10 at 7:18 AM
finance.yahoo.com logoNABRIVA THERAPEUTICS AG Financials (NASDAQ:NBRV)
finance.yahoo.com - May 5 at 1:04 PM
publicnow.com logoNabriva Appoints Gary Sender as Chief Financial Officer (NASDAQ:NBRV)
www.publicnow.com - May 2 at 7:10 AM
finance.yahoo.com logo7:00 am Nabriva Therapeutics appoints Gary Sender as CFO, effective immediately (NASDAQ:NBRV)
finance.yahoo.com - May 2 at 7:00 AM
biz.yahoo.com logoNabriva Therapeutics AG Earnings Call scheduled for 8:30 am ET today (NASDAQ:NBRV)
biz.yahoo.com - April 27 at 8:30 AM
publicnow.com logoNabriva Therapeutics AG Reports Full Year 2015 Financial Results and Provides Development Update (NASDAQ:NBRV)
www.publicnow.com - April 27 at 7:21 AM
biz.yahoo.com logoQ4 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open (NASDAQ:NBRV)
biz.yahoo.com - April 27 at 7:07 AM
publicnow.com logoNabriva Therapeutics AG to Provide Development Update and Announce Full Year 2015 Financial Results; Conference Call on Wednesday, April 27, 2016 (NASDAQ:NBRV)
www.publicnow.com - April 19 at 7:15 AM

Social

What is Nabriva Therapeutics AG's stock symbol?

Nabriva Therapeutics AG trades on the NASDAQ under the ticker symbol "NBRV."

Where is Nabriva Therapeutics AG's stock going? Where will Nabriva Therapeutics AG's stock price be in 2017?

5 brokers have issued 12-month price targets for Nabriva Therapeutics AG's shares. Their predictions range from $13.00 to $22.00. On average, they expect Nabriva Therapeutics AG's stock price to reach $15.80 in the next twelve months.

When will Nabriva Therapeutics AG announce their earnings?

Nabriva Therapeutics AG is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

What are analysts saying about Nabriva Therapeutics AG stock?

Here are some recent quotes from research analysts about Nabriva Therapeutics AG stock:

  • According to Zacks Investment Research, "Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. " (2/4/2017)

  • Wedbush analysts commented, "Nabriva recently reported that LEAP-1 has achieved 60% of its enrollment target, remaining on track to report data from both Ph 3 studies in 2H17 ' we believe both these readouts will be positive. In addition, we believe lefamulin's product profile possesses the key attributes required to take advantage of the commercial opportunity in CABP." (1/31/2017)

Who owns Nabriva Therapeutics AG stock?

Nabriva Therapeutics AG's stock is owned by many different of retail and institutional investors. Top institutional investors include Vivo Capital LLC (18.90%), Novo A S (10.93%), Orbimed Advisors LLC (7.89%), Acuta Capital Partners LLC (3.32%), Franklin Resources Inc. (1.64%) and EcoR1 Capital LLC (1.24%).

Who sold Nabriva Therapeutics AG stock? Who is selling Nabriva Therapeutics AG stock?

Nabriva Therapeutics AG's stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC.

Who bought Nabriva Therapeutics AG stock? Who is buying Nabriva Therapeutics AG stock?

Nabriva Therapeutics AG's stock was bought by a variety of institutional investors in the last quarter, including Novo A S, Vivo Capital LLC, Orbimed Advisors LLC, Acuta Capital Partners LLC, FT Options LLC and Renaissance Technologies LLC.

How do I buy Nabriva Therapeutics AG stock?

Shares of Nabriva Therapeutics AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nabriva Therapeutics AG stock cost?

One share of Nabriva Therapeutics AG stock can currently be purchased for approximately $10.78.

Nabriva Therapeutics AG (NASDAQ:NBRV) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Earnings History Chart

Earnings by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Dividend History Chart

Dividend Payments by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Last Updated on 3/1/2017 by MarketBeat.com Staff